Squalene is a valuable natural substance with several biotechnological applications. In the yeast Saccharomyces cerevisiae, it is produced in the isoprenoid pathway as the first precursor dedicated to ergosterol biosynthesis. The aim of this study was to explore the potential of squalene epoxidase encoded by the ERG1 gene as the target for manipulating squalene levels in yeast. Highest squalene levels (over 1000 μg squalene per 10(9)  cells) were induced by specific point mutations in ERG1 gene that reduced activity of squalene epoxidase and caused hypersensitivity to terbinafine. This accumulation of squalene in erg1 mutants did not significantly disturb their growth. Treatment with squalene epoxidase inhibitor terbinafine revealed a limit in squalene accumulation at 700 μg squalene per 10(9)  cells which was associated with pronounced growth defects. Inhibition of squalene epoxidase activity by anaerobiosis or heme deficiency resulted in relatively low squalene levels. These levels were significantly increased by ergosterol depletion in anaerobic cells which indicated feedback inhibition of squalene production by ergosterol. Accumulation of squalene in erg1 mutants and terbinafine-treated cells were associated with increased cellular content and aggregation of lipid droplets. Our results prove that targeted genetic manipulation of the ERG1 gene is a promising tool for increasing squalene production in yeast.

The ability of Escherichia coli to grow on a series of acetylated and glycosylated compounds has been investigated. It is surmised that E. coli maintains low levels of nonspecific esterase activity. This observation may have ramifications for previous reports that relied on nonspecific esterases from E. coli to genetically encode nonnatural amino acids. It had been reported that nonspecific esterases from E. coli deacetylate tri-acetyl O-linked glycosylated serine and threonine in vivo. The glycosylated amino acids were reported to have been genetically encoded into proteins in response to the amber stop codon. However, it is our contention that such amino acids are not utilized in this manner within E. coli. The current results report in vitro analysis of the original enzyme and an in vivo analysis of a glycosylated amino acid. It is concluded that the amber suppression method with nonnatural amino acids may require a caveat for use in certain instances.The central question addressed in this paper is whether the glycosylated amino acids GlcNAc-Ser and GalNAc-Thr have been genetically encoded into proteins in vivo (1, 2). The reports for the incorporation of these two amino acids are unique from all other reports (3) that have incorporated unnatural amino acids using the recoded UAG codon and Methanococcus jannaschii orthogonal pairs in that these two amino acids required further processing by the host organism before incorporation (see Fig. 1). Here we posit that the primary barrier to their incorporation would appear to be the fact that the host organism used in the original reports, Escherichia coli, maintains very low levels of nonspecific esterase activity. In fact, the original reports used citations from mammalian biology to substantiate the nonspecific esterase mechanism (see below).E. coli is likely the most thoroughly studied microorganism. This is especially true in regard to carbohydrate and amino acid uptake and utilization (4). Therefore, it should not be surprising that it has long been known that esterified carbon sources are not metabolized by E. coli in standard assays used to probe for microorganism lipase and esterase activity (5). Such results and our current analysis underscore the limitations of the reports that triacetyl O-linked glycosylated amino acids (GlcNAc-Ser and GalNAc-Thr) were deacetylated in E. coli by endogenous "nonspecific" esterases. The deacetylated amino acids were then believed to have been genetically encoded into full-length proteins in vivo (1, 2).In these previous studies the glycosylated amino acids were provided to the growth media as their tetraacetate analogs, and it was construed from the mass spectra and lectin binding assays that the ester groups of the saccharide had all been hydrolyzed. The notion that E. coli rapidly hydrolyzes a simple ester is not easily reconciled with what is commonly observed when the ester functional group is introduced into cultures of E. coli. For example, we were prompted by reports that claimed to have harvested ␤-hydroxy esters f...

Pdr16p is considered a factor of clinical azole resistance in fungal pathogens. The most distinct phenotype of yeast cells lacking Pdr16p is their increased susceptibility to azole and morpholine antifungals. Pdr16p (also known as Sfh3p) of Saccharomyces cerevisiae belongs to the Sec14 family of phosphatidylinositol transfer proteins. It facilitates transfer of phosphatidylinositol (PI) between membrane compartments in in vitro systems. We generated Pdr16pE235A, K267A mutant defective in PI binding. This PI binding deficient mutant is not able to fulfill the role of Pdr16p in protection against azole and morpholine antifungals, providing evidence that PI binding is critical for Pdr16 function in modulation of sterol metabolism in response to these two types of antifungal drugs. A novel feature of Pdr16p, and especially of Pdr16pE235A, K267A mutant, to bind sterol molecules, is observed.